CannaSoul Analytics

What CannaSoul Analytics does

CannaSoul Analytics is an Israel-based cannabis-focused drug discovery and analytical services company founded by Prof. Dedi Meiri of the Technion – Israel Institute of Technology. Its core offering is a proprietary analytical platform combining multi-modal mass spectrometry (HPLC, UPLC, Orbitrap LC-MS/MS, QQQ LC-MS/MS, QQQ GC-MS/MS, ICP-MS) with proprietary knowhow and a clinical trial framework to support active compound identification from botanical extract through clinically approved formulation. Published methodologies include comprehensive phytocannabinoid profiling across 94+ cannabinoids from 10 subclasses, de novo transcriptome assembly of cannabis cultivars, postharvest storage optimization, and full-spectrum extract microdepot technology. The platform can detect molecules down to ppb levels and screen 260+ pesticides.

The company monetizes through four primary streams: contract analytical testing services (potency, pesticides, heavy metals, microbial, toxins) for medical cannabis producers under IMC-GMP and ISO/IEC 17025; R&D and contract research including bioanalytical method development under GCLP for clinical/preclinical studies; IP licensing of proprietary methods and processes; and clinical trial framework services. Pricing is quote-based per project with Net+30 payment terms; revenue is not publicly disclosed.

CannaSoul operates through six named entities — the parent Cannasoul Group plus subsidiaries Cannasoul Lab Services (ISO 17025/IMC-GMP testing facility in Gan Shmuel), MyPlant Bio (cell-based disease models for strain screening), Psyga Bio (psilocybin drug discovery), Femestro (phyto-cannabinoid therapies for women's health), and two research-stage entities (Nidra Logic, CaVnox). Strategic investor InterCure acquired a 28% stake in November 2025 with a path to 51%, and TAO Synergies invested $4M in November 2023. Operating geographies are limited to Israel, with export compliance frameworks covering US, European, and Canadian regulations.

Name

CannaSoul Analytics

Legal name

Cannasoul Analytics Ltd.

Website

https://cannasoul.co.il

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

CannaSoul Analytics is an Israel-based cannabis drug discovery and analytical services firm using proprietary mass spectrometry platforms to support pharmaceutical companies and medical cannabis producers with compound identification, regulatory testing, and clinical bioanalysis.

Ownership category

akta.pro rank

Product category

Cannabis Analytics & Drug Discovery Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Analytical Development & Method Validation (CMC) (HLAGAHAF)

Keywords

• Cannabis analytics
• Analytical testing services
• Bioanalytical services
• Drug discovery
• Cannabis therapeutics

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Analytical Testing Services: Contract analytical testing services for pharmaceutical companies and cannabis producers, including batch release testing under IMC-GMP and ISO 17025 accreditation. Services include potency testing, pesticide analysis, heavy metals, microbial analysis, and toxins testing.
2. R&D and Contract Research: Research and development services including analytical method development, preclinical and clinical study support, and extraction/isolation services for botanical compounds.
3. IP Licensing: Licensing of proprietary analytical methods, processes, and technologies developed by the company. IP includes analytical approaches for cannabis profiling and drug development methodologies.
4. Clinical Trial Framework Services: Support for clinical trials including bioanalysis of samples from preclinical (non-GLP) and clinical (GCLP) studies using advanced analytical capabilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

CannaSoul Analytics is a cannabis-focused drug discovery and contract research company that provides proprietary analytical services, bioanalytical testing, extraction and isolation of rare cannabinoids, and preclinical/clinical study support for pharmaceutical companies and medical cannabis producers. The company combines a mass-spectrometry-based analytical platform with published methodologies (Cannabinoidomics, transcriptome assembly, comprehensive phytocannabinoid profiling) to advance cannabis-based therapeutics from botanical extract through clinically approved formulation.

Product overview

CannaSoul Analytics operates as a cannabis innovation, research, and technology incubator offering a comprehensive drug discovery platform. The core Cannasoul Group provides proprietary analytical services, bioanalytics, extraction and isolation capabilities, and preclinical/clinical study support. The portfolio includes five subsidiaries: Cannasoul Lab Services (ISO 17025-accredited medical cannabis testing laboratory for batch release), MyPlant Bio (cell-based disease models for therapeutic screening), Femestro (phyto-cannabinoid therapies for women's health), and Psyga Bio (psychedelic mushroom therapeutics). The company bridges botanical medicine and the pharmaceutical industry, supporting compound identification from extraction through clinical formulation.

Differentiator

Problem solved

Functional benefit

Products and services

• CannaSoul Group Drug Discovery Services End-to-end drug discovery services for pharmaceutical companies developing cannabis-based therapeutics, including analytical method development, bioanalytics, extraction and isolation of rare cannabinoids, formulation development, and preclinical/clinical study support under GCLP accreditation, from botanical extract through clinically approved formulation.
• CannaSoul Lab Services ISO/IEC 17025 and IMC-GMP accredited analytical testing laboratory for medical cannabis producers, providing batch release testing including potency (17 cannabinoids), terpenes, flavonoids, pesticides (260+), heavy metals, microbial analysis, toxins, and analytical method development compliant with Israeli, US, European, and Canadian regulations.
• MyPlant Bio Cell-Based Screening Cell-based disease model screening services for cannabis cultivators and researchers, building a library of indications across immunology, inflammation, respiratory, cardiovascular, endocrinology, gastroenterology, dermatology, neurology, and orthopedics to discover therapeutic effects of cannabis strains on specific medical conditions.
• Femestro Women's Health Therapeutics Development of innovative phyto-cannabinoid-based therapies targeting hormone-related diseases and chronic conditions in women's health, using proprietary compounds and pathways specific to female-specific health conditions.
• Psyga Bio Psychedelic Drug Discovery Drug discovery and development services from psilocybin mushrooms, using CannaSoul's proprietary analytical platform and clinical trial framework to identify active compounds and formulations for therapeutic benefits in psychiatric conditions.

Quantifiable outcome

• 94 phytocannabinoids identified and profiled across 36 medical Cannabis plants
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Technion - Israel Institute of TechnologycoreStrategic or Co-development PartnerCannasoul was founded by Prof. Dedi Meiri from the Technion and is backed by the institution's scientific capabilities. The company maintains close research ties with Prof. Meiri's lab at the Technion, which heads the Cannabis DB project and Cancer Biology and Cannabinoid Research Lab. The Technion logo appears on company materials as a founding partner.
• MyPlant BiocoreOthersMyPlant Bio is a subsidiary of Cannasoul Analytics, incorporated in 2018. It develops cell-based disease models to understand biological effects of cannabis and other plant compounds. The subsidiary screens plant compounds using high-throughput technology and maintains a database of analytics and biological effects.
• Psyga BiocoreOthersPsyga Bio is a subsidiary of Cannasoul Analytics, focused on drug discovery from psychedelic mushrooms. Founded by Prof. Dedi Meiri, it uses Cannasoul's proprietary analytical platform and clinical trial framework for active compound identification from psilocybin mushrooms.
• Cannasoul Lab ServicescoreOthersCannasoul Lab Services is a subsidiary providing dedicated medical cannabis analytical testing services. Operates under ISO 17025 and IMC-GMP certifications, offering batch release testing compliant with Israeli, US, European, and Canadian regulations.
• FemestrocoreOthersFemestro is a subsidiary developing innovative phyto-cannabinoid-based therapies for women's health. Led by experienced pharmaceutical professionals, it addresses hormone-related diseases and chronic conditions using proprietary phyto-cannabinoids.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cannabis NBOG / Cannasoul Lab Services peers - Steep Hill Labs: Steep Hill was one of the pioneering cannabis analytical testing laboratories, providing potency, contaminant, and terpene profiling for licensed producers — directly comparable to Cannasoul Lab Services' IMC-GMP batch release and ISO 17025 testing offering.
• CannaSafe Analytics: CannaSafe is a US-based ISO 17025-accredited cannabis testing lab providing potency, pesticides, heavy metals, microbial, and terpene analysis — the closest US analog to Cannasoul Lab Services in regulatory scope and customer base.
• Anresco Laboratories: Anresco is an independent analytical testing laboratory with established cannabis testing capabilities (potency, contaminants, mycotoxins) and broader food/pharma testing — a direct competitor to Cannasoul Lab Services' analytical testing streams.
• Cannabics Pharmaceuticals: Cannabics Pharmaceuticals is a cannabis-focused drug development company pursuing cannabinoid-based therapeutics for cancer and other indications — comparable to Cannasoul's drug-discovery-from-botanicals model and Femestro/M Psyga Bio pipeline subsidiaries.
• InnoCan Pharma: InnoCan Pharma is a pharma-tech company developing cannabinoid-based therapeutics with a focus on topical and injectable delivery — comparable to Cannasoul's Femestro subsidiary in pursuing indication-specific phytocannabinoid therapies rather than generic cannabis products.

Broad incumbents

• Eurofins Scientific: Eurofins is a global testing-services conglomerate with established cannabis and pharmaceutical analytical offerings including mass-spectrometry-based bioanalysis and method validation — a broad incumbent whose cannabis franchise competes with both Cannasoul Lab Services and the pharma services side of the platform.
• SGS SA: SGS is one of the world's largest testing, inspection, and certification companies with cannabis and pharmaceutical analytical services across multiple geographies — a broad incumbent whose scale and global lab footprint could absorb cannabis testing demand Cannasoul targets.
• InterCure (parent): InterCure is Cannasoul's strategic investor (28% stake) and one of Israel's largest medical cannabis operators with international distribution — comparable as a vertically-integrated cannabis operator that uses Cannasoul's analytics and validates its commercial pipeline.
• Tilray Brands: Tilray is a global cannabis-lifestyle and pharmaceutical cannabis company with pharma-grade production and global distribution — a broad incumbent whose pharma division represents the type of multinational partner Cannasoul's analytical platform is built to serve.
• GW Pharmaceuticals (Jazz Pharmaceuticals): GW Pharmaceuticals (now part of Jazz) developed Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug — the gold-standard benchmark for cannabis-derived pharmaceutical development that Cannasoul's drug-discovery pipeline is positioning toward.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/35711926

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CannaSoul Analytics